Magazine Article | July 1, 2022

Why You Shouldn't Neglect The Pre-IND Meeting

Source: Life Science Leader

By Michael Cooper

Most regulatory professionals could sketch a map of the pharmaceutical product development life cycle in short order, starting with the IND application as the first milestone, followed by Phase 1, 2, and 3 clinical trials, then NDA or BLA submission, followed by post-approval life cycle maintenance or Phase 4 clinical trials.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: